Avance Clinical Strengthens Korea Focus: Seoul Meeting Highlights Growth, Partnerships, and Regional Collaboration

Meeting Priorities and Outcomes

The discussions highlighted four priority areas:

• Expanding Avance Clinical’s Footprint in Korea – Establishing a new local office, expanding the team, and strengthening on-the-ground capabilities to support Korean biotech companies in global clinical development.
• Growing Korean Biotech Interest in Australia – Supporting biotechs conducting early-phase trials in Australia, driven by the Australian Advantage of faster timelines, globally accepted data, and up to 43.5% R&D rebate.
• Two-Way Global Pathways – Leveraging Avance Clinical’s global presence, particularly in the United States, to promote Korea as an attractive clinical trial destination for US biotechs while creating seamless trial pathways between Australia, Korea, and the US.
• Partnership Opportunities – Exploring joint initiatives to enhance trial efficiency, broaden patient access, and identify avenues for government and industry support.

Shared Opportunities For Growth

“This meeting underscored the shared opportunity to connect South Australia’s strengths with Korea’s world-class clinical trial ecosystem,” said Mark Harvill, Chief Executive Officer, Avance Clinical. “By deepening ties, we can accelerate Avance Clinical’s growth in Korea and create new opportunities for Korean biotechs to access early-phase advantages in Australia, particularly in Oncology and other areas of unmet medical need.”